Key result
Gut microbiome regulates cardiovascular risk and emerges as a target to prevent cancer therapy-related cardiac dysfunction.
Why the study?
Cancer survivors face higher risks of cardiovascular disease and premature mortality, but modifiable underlying mechanisms remain poorly understood.
The gut microbiome represents a promising avenue for understanding, predicting, and preventing cancer therapy-related cardiac dysfunction in cancer survivors.
Answers are grounded in this paper and cite their sources.
Underscores need for CVD surveillance in cancer survivors; leaves open optimal prevention strategies.
As cancer survival rates improve, the long-term burden of treatment has become increasingly evident. Cancer survivors face a markedly higher risk of cardiovascular-related complications and premature, non-cancer-related mortality. In particular, cardiovascular disease (CVD) is disproportionately prevalent, with survivors approximately 40% more likely to develop and die from CVD compared to the general population. Although this increased morbidity reflects both acute cardiotoxic events and the later development and progression of more chronic CVDs, traditionally viewed as direct consequences of cancer therapies, the underlying mechanisms, especially those that are feasible to modify, are poorly understood. Emerging evidence positions the gut-heart axis as a central regulator of cardiovascular risk in cardio-oncology. This avenue is especially compelling to explore as the gut microbiome is well documented to be altered by cancer therapies, including chemotherapy, immune checkpoint inhibitors, targeted therapies, and radiation, with profound and persistent changes in diversity, composition and function widely reported across clinical cohorts. Comparable microbial changes have been observed in non-cancer cohorts with cardiovascular disease. For example, specific microbial metabolites have been reported to exert cardiovascular protective benefits in hypertension. Thus, there is a compelling opportunity to explore the gut microbiome to advance our understanding and ability to prevent cardiovascular disease in cancer survivors. This review synthesises current evidence linking the gut microbiome to cancer therapy-related cardiac dysfunction (CTRCD), evaluates microbial metabolites as predictive biomarkers of cardiotoxicity, and discusses microbiome-targeted modulation as an emerging strategy for improving cardiovascular outcomes in cancer survivors.
No takes yet. Share an insight, caveat, or question.
Chan et al. (2026) conducted a review in Cancer therapy-related cardiac dysfunction (CTRCD). Gut microbiome modulation was evaluated. The gut microbiome is a central regulator of cardiovascular risk in cardio-oncology, presenting a compelling target to prevent cancer therapy-related cardiac dysfunction in cancer survivors.
Synapse has enriched 10 related papers. Consider them for comparative context: